[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"revascularization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:revascularization":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,58,94,116,145,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100613651","surgical-versus-percutaneous-revascularization-in-patients-with-reduced-left-ventricular-function-stich-30-nl-100613651",false,"NCT07269366","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function (STICH 3.0-NL)","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function","STICH 3*0-NL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* LVEF≤ 40%\n* Angina pectoris, CCS≥2 and\u002For hospitalization for ACS or heart failure within 1 year prior to randomization\n* Multivessel CAD (2-3 vessel-disease with coronary lesions \\>70% and involvement of proximal LAD, and\u002For LM stenosis of \\>50%). Target vessels are determined by the local Heart Time\n* Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team\n* Written informed consent\n\nExclusion Criteria:\n\n* ACS \\\u003C 48 hours before randomization\n* Valvular\u002Fstructural heart disease requiring intervention\n* Contra-indications to DAPT\n* Non-cardiac condition with life expectancy \\\u003C 1 year\n* Previous CABG\n* Decompensated HF at the time of inclusion","ALL","18 Years",{"count":20,"type":21},358,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized multicenter trial compares coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) in 358 patients with ischemic left ventricular dysfunction and multivessel coronary disease. The study evaluates differences in survival, major cardiovascular events, and quality of life over 4 years, and contributes to the international STICH 3.0 collaboration assessing long-term outcomes.",[27,28,29,30,31,32,33,34],"Coronary Artery Disease","Coronary Artery Disease (CAD)","Multivessel Coronary Artery Disease","CABG","CABG in Low EF","Heart Failure","PCI","Revascularization",[36,37,38,39,40,41,42,43,44],"coronary artery","coronary artery disease","heart failure","low ejection fraction","hfref","cabg","coronary artery bypass graft","pci","revascularization","RECRUITING","2026-05-07",{"date":48,"type":49},"2026-05-12","ACTUAL",{"date":51,"type":21},"2026-05",{"date":53,"type":21},"2034-05",{"name":55,"class":56},"University Medical Center Groningen","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":68,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100568814","phase-3-improving-mobility-after-revascularization-in-peripheral-artery-disease-100568814","NCT06686121","Improving Mobility After Revascularization in Peripheral Artery Disease","IMProving Mobility After revasCularizaTion in Peripheral Artery Disease: The IMPACT PAD Trial","IMPACT PAD","Inclusion Criteria:\n\nSuccessful lower extremity revascularization for disabling PAD performed at least 30 days before baseline testing and between 30 and 100 days before randomization.\n\nExclusion Criteria:\n\n1. History of leg amputation, not including toe and partial foot amputation\n2. Active gangrene\n3. Active limb threatening ischemia\n4. Already exercising at a level consistent with exercise intervention, using investigator discretion.\n5. Unstable angina\n6. Unwilling to drink study beverages\n7. Unwilling to adhere to the interventions and complete follow-up testing\n8. Currently taking sildenafil, tadalafil, or related drugs.\n9. Unwilling to accept randomization into either group (home-based exercise or attention control)\n10. Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and\u002For unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial.\n11. History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.\n12. Baseline blood pressure \\\u003C100\u002F45.\n13. Wheelchair confinement or requiring a walker to ambulate\n14. Walking is limited by a condition other than PAD\n15. Current foot ulcer\n16. Planned major surgery, coronary revascularization, or lower extremity revascularization during the next 12 months\n17. Major medical illness including lung disease requiring oxygen, Parkinson's disease, or a life-threatening illness with life expectancy less than six months.\n18. Allergy to beetroot juice\n19. Currently consuming one cup or more of beets daily. Participants will be asked to decrease beet consumption to less than one cup of beets per day for 14 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial.\n20. Participation in or completion of a clinical trial in the previous three months, using investigator discretion for trials that may not impact study participation or outcome measures of the IMPACT PAD Trial.\n21. Visual impairment that limits walking ability.\n22. Unable to communicate in English, unless the participant communicates in Spanish and is enrolled at a site that can deliver the intervention in Spanish. All sites with a Spanish speaking coordinator and interventionist will be able to enroll Spanish-speaking participants. While investigators aim to be as inclusive as possible, resources are not available to allow inclusion of people speaking languages that are not Spanish or English.\n23. Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.\n24. Planning to begin a supervised treadmill exercise program in the next 12 months.\n25. Heart attack or stroke in previous three months prior to baseline testing.\n26. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.",{"count":67,"type":21},386,[69],"PHASE3","Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.\n\nInvestigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity.\n\nIn a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).",[72,73,74,75,34],"Peripheral Artery Disease","Intermittent Claudication","Peripheral Vascular Disease","Mobility Limitation",[77,78,79,34,80,81,82,83],"Behavior Change","Patient Reported Outcome Measures","Mobility","Peripheral artery disease","Intermittent claudication","6-minute walk","Oxidative stress","2025-08-23",{"date":86,"type":49},"2025-08-26",{"date":88,"type":49},"2025-08-04",{"date":90,"type":21},"2032-08-01",{"name":92,"class":56},"Northwestern University",7,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":57},"100587146","study-on-the-trans-carotid-artery-occlusion-shunt-system-100587146","NCT06924593","Study on the Trans-Carotid Artery Occlusion Shunt System","Study on the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System for Carotid Artery Revascularization During Endovascular Treatment","Inclusion Criteria:\n\n* Age \\> 18 years;\n* For patients diagnosed with carotid artery stenosis and planned to undergo transcarotid artery endovascular revascularization, one of the following conditions must be met:\n\n  1. Symptomatic carotid artery stenosis: The degree of stenosis is determined by non-invasive imaging or angiography to be \\> 50%, and the patient has a history of stroke (mild or non-disabling), transient ischemic attack (TIA), and\u002For amaurosis fugax within 180 days before the operation.\n  2. Asymptomatic carotid artery stenosis: The degree of stenosis is determined by non-invasive imaging or angiography to be \\> 70%, and the patient has not experienced any neurological symptoms within 180 days before the operation.\n* The modified Rankin Scale (mRs) score ≤ 2 before enrollment.\n* The patient must meet at least one of the following important anatomical or comorbid high-risk conditions in order to be included in the study:\n\nAnatomical high-risk:\n\nA. Contralateral carotid artery occlusion; B. Presence of tandem stenosis in the internal carotid artery with a stenosis degree \\> 70%; C. Carotid artery stenosis above the C2 vertebral body; D. Restenosis after previous ipsilateral carotid endarterectomy; E. Bilateral carotid artery stenosis requiring treatment (treatment of the contralateral vessel should be carried out at least 30 days after the operation); F. \"Difficult neck\" suitable for the transcarotid approach as evaluated by the researcher, including but not limited to: history of previous neck radiotherapy, history of previous radical neck lymph node dissection, neck stoma or limited cervical spine mobility.\n\nComorbid high-risk:\n\nG. The patient's age is ≥ 70 years old; H. The patient has coronary artery disease involving \\> 2 vessels and has a history of angina pectoris of any severity; I. The patient has a history of angina pectoris, with Canadian Cardiovascular Society (CCS) angina class 3 or 4, or unstable angina pectoris (defined as resting angina pectoris accompanied by electrocardiogram changes); J. The patient has congestive heart failure (CHF) - New York Heart Association (NYHA) functional class 3 or 4; K. The patient is known to have severe left ventricular dysfunction with a left ventricular ejection fraction (LVEF) \\\u003C 30%; L. The patient has experienced a myocardial infarction within 72 hours to 6 weeks before the operation; M. The patient has severe pulmonary disease (chronic obstructive pulmonary disease, COPD), with a forced expiratory volume in one second (FEV1) \\\u003C 50% (predicted value), or has been receiving long-term oxygen therapy, or has an arterial partial pressure of oxygen (PO2) ≤ 60 mmHg (room air) at rest; N. The patient has permanent contralateral cranial nerve injury; O. The patient has chronic renal insufficiency (serum creatinine \\> 2.5 mg\u002FdL).\n\n* The diameter of the common carotid artery on the target lesion side is \\> 6 mm;\n* The patient is able to understand the purpose of the trial, voluntarily participates in this study, signs the informed consent form, and is willing to complete the follow-up according to the requirements of the protocol.\n\nExclusion Criteria:\n\n* Anatomical exclusion criteria:\n\nThere are extensive atherosclerotic plaques in the proximal part of the common carotid artery on the target lesion side, making the safe operation of the surgery difficult; There are lesions in the access area of the common carotid artery on the target lesion side and its proximal part towards the heart; The distance from the superior border of the clavicle on the target lesion side to the bifurcation of the common carotid artery is less than 5 cm; A stent or graft has been implanted in the carotid artery on the target lesion side; There are acute or subacute thrombosis, arteriovenous malformations at the target lesion or adjacent areas; Severe calcification or tortuosity at the target lesion site makes it difficult to deliver the instruments to the designated location; The target carotid artery is completely occluded;\n\n* Known to have uncontrollable hypertension (systolic blood pressure continuously ≥ 180 mmHg or diastolic blood pressure continuously ≥ 110 mmHg);\n* Combined with symptomatic severe stenosis of other blood vessels (including intracranial and extracranial vessels);\n* The patient has experienced an ischemic stroke within 3 months, and the stroke affects the evaluation of the endpoints;\n* There has been spontaneous intracranial hemorrhage within 12 months;\n* Carotid artery stenosis not caused by atherosclerosis (such as dissection, fibromuscular dysplasia, etc.);\n* There are other heart diseases that may lead to embolism: such as left ventricular aneurysm, intracardiac filling defect, cardiomyopathy, artificial aortic valve or artificial mitral valve, calcific aortic stenosis, endocarditis, mitral stenosis, atrial septal defect, atrial septal aneurysm or left atrial myxoma, etc.;\n* Severe dementia or other nervous system diseases that may interfere with the evaluation of neurological function;\n* Advanced heart failure;\n* Chronic atrial fibrillation; Paroxysmal atrial fibrillation with an episode within 6 months or paroxysmal atrial fibrillation requiring long-term anticoagulant therapy;\n* Myocardial infarction occurred within 72 hours before the operation;\n* Coronary artery bypass grafting (CABG), endovascular stent surgery, cardiac valve surgery or vascular surgical procedures have been or will be performed within 30 days before and after the operation;\n* There is an active bleeding tendency or severe coagulation dysfunction; There has been gastrointestinal bleeding within 30 days before the operation, which will affect antiplatelet therapy;\n* Hemoglobin (Hgb) \\\u003C 8 gm\u002FdL, platelet count \\\u003C 90×10\\^9\u002FL or a history of heparin-induced thrombocytopenia;\n* Patients with abnormal liver and kidney function before the operation \\[Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) exceeding 5 times the upper limit of the normal value; Serum creatinine (Cr) \\> 3.0mg\u002FdL (265.2μmol\u002FL) or end-stage renal disease receiving hemodialysis\\];\n* Patients known to be allergic to contrast agents, stent and delivery device materials (referring to nitinol, PTFE, nylon polymer materials); Patients known to have contraindications to anticoagulant and antiplatelet drugs;\n* Intracranial tumors or other malignant tumors;\n* Life expectancy is less than 1 year;\n* Women who plan to become pregnant, are pregnant or are breastfeeding;\n* Patients who are participating in other clinical trials at the same time and have not withdrawn from the trials;\n* Patients who are judged by the researcher as not suitable for participating in this clinical trial.",{"count":102,"type":21},162,[24],"The objective of the study is to evaluate the Safety and Efficacy of the Trans-Carotid Artery Occlusion Shunt System for Carotid Artery Revascularization during Endovascular Treatment",[34,106,107],"Carotid Artery Stenosis","Carotid Artery Diseases",{"date":109,"type":49},"2025-08-07",{"date":111,"type":49},"2025-06-30",{"date":113,"type":21},"2025-12-31",{"name":115,"class":56},"Shenzhen Wecan Medical Technology Co.,Ltd",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":126,"studyType":127,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100415546","ccta-improves-clinical-management-of-stable-chest-pain-100415546","NCT04691037","CCTA Improves Clinical Management of Stable Chest Pain","Improving the Clinical Management of Stable Chest Pain Based on Imaging: a Registry of Computed Tomography Coronary Angiography","CICM-SCP","Inclusion Criteria:\n\n* symptomatic patients with SCP suspected of obstructive CAD.\n* referred for CCTA for the assessment of SCP.\n* ≥18 years of age.\n* signed informed consent.\n\nExclusion Criteria:\n\n* acute coronary syndromes\n* previous CAD or coronary revascularization\n* nonsinus rhythm\n* cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons",{"count":125,"type":21},50000,"3 Years","OBSERVATIONAL","The investigator aims to prospectively enroll patients who were referred for coronary computed tomography angiography (CCTA) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent CCTA according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary. This study will determine if CCTA-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.",[130,131,132,133,34,134,27],"Coronary Computed Tomography Angiography","Stable Chest Pain","Optimal Medical Therapy","Invasive Coronary Angiography","Major Adverse Cardiovascular Events","2024-03-26",{"date":137,"type":49},"2024-03-28",{"date":139,"type":49},"2016-01-01",{"date":141,"type":21},"2030-01-01",{"name":143,"class":56},"Tianjin Chest Hospital",4,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":57},"100480180","percutaneous-coronary-revascularization-versus-coronary-artery-bypass-grafting-for-multivessel-disease-in-patients-with-left-ventricular-dysfunction-proverb-100480180","NCT05532631","Percutaneous Coronary RevascularizatiOn VERsus Coronary-Artery Bypass Grafting for Multivessel Disease in Patients With Left Ventricular Dysfunction (PROVERB)","PROVERB","Inclusion Criteria:\n\n* Age ≥18 years\n* Left ventricle ejection fraction ≤35% measured by echocardiography, cardiac magnetic resonance imaging ventriculogram or gated Single Photon Emission Computed Tomography ventriculogram\n* Multivessel disease suitable for revascularization:\n\n  * Three vessel disease\n  * Two vessel disease involving left main or proximal left anterior descending artery\n* Clinical and anatomic eligibility for both percutaneous coronary intervention (PCI) and Coronary artery bypass grafting (CABG) as agreed to by the local Heart Team (interventionalist determines PCI appropriateness and eligibility; cardiac surgeon determines surgical appropriateness and eligibility)\n* Ability to sign informed consent and comply with all study procedures, including follow-up for at least two years\n* Affiliation to health insurance\n\nExclusion Criteria:\n\n* Prior:\n\n  * PCI of any coronary artery lesions within 6 months prior to randomization\n  * CABG at any time prior to randomization\n* Ongoing cardiogenic shock at the time of coronary angiogram (SBP\\\u003C 90 mmHg with clinical signs of low output or patients requiring inotropic agents)\n* Contra indication for PCI or CABG determined by the heart team\n* Indication for another cardiac surgery (i.e. valvular surgery, aortic repair…) if CABG is performed\n* ST elevation myocardial infarction \\\u003C 30 days\n* Non-cardiac illness with a life expectancy of less than 24 months\n* Current participation in other investigational drug or device studies\n* Women who are pregnant or nursing\n* Females of childbearing potential without effective method of birth control\n* Patients who are under tutorship or curatorship\n* Patient on AME (state medical aid)",{"count":153,"type":21},1040,[24],"A short description, 5000 characters Ischemic cardiomyopathy related to coronary artery disease is currently the leading cause of heart failure. When it is responsible for heart failure, the coronary artery disease likely involves 2 or 3 vessels. Percutaneous coronary angioplasty, which is the other available technique for coronary revascularization, has never been evaluated in this indication. The results of retrospective registries studying the strategy for multivessel revascularization in patients with heart failure are inconsistent and no randomized study has been performed so far. Currently, ESC guidelines recommends to perform coronary-artery bypass grafting (IB) or percutaneous coronary intervention (IIa C) with the acknowledgement that percutaneous coronary intervention has never been properly evaluated in this setting. However, it has been previously demonstrated that left ventricle dysfunction significantly increases mortality and morbidity during and after cardiac surgery (3-10% mortality when LVEF is ≤30%). Moreover, the technical progresses in stent development and manufacturing have led to a dramatic decrease in the incidence of stent thrombosis and in-stent restenosis. Therefore, we hypothesize that percutaneous coronary angioplasty may be an attractive strategy for revascularization in patients with multi-vessel disease and left ventricle dysfunction, who are at high risk of surgical complication. Thus, we aim to test the hypothesis that percutaneous coronary intervention is non-inferior to coronary-artery bypass grafting for revascularization in patients with multivessel disease and left ventricle dysfunction.\n\nThe main objective is to demonstrate that percutaneous coronary angioplasty is non-inferior to coronary-artery bypass grafting for multivessel revascularization in patients with left ventricular dysfunction on major cardiac and cerebrovascular events (MACCE).\n\nMethod:A Prospective Randomized Open label, Blinded Endpoint, parallel-group, active controlled, non-inferiority, multicenter trial.",[32,34],[32,158,159,160],"Multi-vessel disease","coronary artery bypass grafting","percutaeous coronary intervention","2023-03-20",{"date":163,"type":49},"2023-03-22",{"date":165,"type":49},"2023-03-16",{"date":167,"type":21},"2033-07-16",{"name":169,"class":56},"Assistance Publique - Hôpitaux de Paris",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":181,"studyType":127,"phases":4,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":57},"100486822","the-evolution-and-prognosis-of-moyamoya-disease-100486822","NCT05619068","The Evolution and Prognosis of Moyamoya Disease","Imaging Investigation on the Evolution and Prognosis of Moyamoya Disease","Inclusion Criteria:\n\n* Patients with MMD: Conventional angiography or MRI examination conforms to the Guidelines for Diagnosis and Treatment of MMD (Neurol Med Chir (Tokyo) 52, 245-266, 2012), It is characterized by stenosis or occlusion of the end of the internal carotid artery, anterior cerebral artery and\u002For the beginning of the middle cerebral artery of unknown cause, accompanied by dilatation of the perforating artery at the base of the brain or of capillaries on the surface of the brain, i.e., the formation of smoke vessels. Sign the informed consent. Older than 10 and younger than 60. The education level of patients reached primary school or above (years of education ≥6).\n\nExclusion Criteria:\n\n* Patients with massive cerebral infarction, multiple paraventricular ischemic foci, or significantly enlarged ventricular hydrocephalus after intracerebral hemorrhage. Patients with vascular diseases caused by immune system disease. Patients can not cooperate to complete the cognitive function test. There are other neuropsychiatric diseases that affect cognitive function (such as Alzheimer's disease, Parkinson's disease, depression, anxiety disorder, cerebral hemorrhage, hydrocephalus, craniocerebral trauma, etc.). Patients with contraindications of magnetic resonance examination (patients with pacemakers, nerve stimulators, artificial metal heart valves and other metal foreign bodies) or unable to complete image collection.","10 Years","60 Years",{"count":180,"type":21},300,"5 Years","To investigate the evolution of imaging appearances and cognitive function of Moyamoya disease (MMD) and to establish a prognosis evaluation system based on imaging biomarkers in MMD. The study may be helpful to optimize and improve the diagnosis and pretreatment assessment of MMD, and provide an important theoretical supplement to the existing guidelines for the management of MMD.",[184,34,185,186],"Moyamoya Disease","Cognitive Impairment","Functional Impairment",[188,34,189,190],"Moyamoya disease","Cognitive impairment","Functional impairment","2022-12-19",{"date":193,"type":49},"2022-12-21",{"date":195,"type":49},"2022-09-01",{"date":197,"type":21},"2027-12-31",{"name":199,"class":56},"Chinese PLA General Hospital"]